• Announced important clinical milestones for ACI-24 vaccine in Alzheimer's disease and Down Syndrome
  • Company record high, period end cash position of approximately CHF 200 million that is expected to extend our cash runway to Q3 2021, excluding potential incoming milestones
  • Successfully issued 10 million new shares via three offerings to raise gross proceeds of USD 117.5 (CHF 116.3) million

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the three and nine months ended September 30, 2018.